179 related articles for article (PubMed ID: 33303972)
1. SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer.
Wang Y; Xue Q; Zheng Q; Jin Y; Shen X; Yang M; Zhou X; Li Y
Lab Invest; 2021 Apr; 101(4):463-476. PubMed ID: 33303972
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between Expression of TGF-β1, Smad2, Smad4 and Prognosis
of Patients with Resected Non-small Cell Lung Cancer].
Xie M; He C; Wei S
Zhongguo Fei Ai Za Zhi; 2015 Sep; 18(9):543-8. PubMed ID: 26383977
[TBL] [Abstract][Full Text] [Related]
3. [The role of Smad4 and MAPK proteins in signal transduction pathway in non-small cell lung cancer].
Tong XD; Liu HX; Zhao HR; Xu SG; Li Y; Han LB; Zhang L
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):741-5. PubMed ID: 17366784
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-205 targets SMAD4 in non-small cell lung cancer and promotes lung cancer cell growth in vitro and in vivo.
Zeng Y; Zhu J; Shen D; Qin H; Lei Z; Li W; Liu Z; Huang JA
Oncotarget; 2017 May; 8(19):30817-30829. PubMed ID: 28199217
[TBL] [Abstract][Full Text] [Related]
5. Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
Ziemke M; Patil T; Nolan K; Tippimanchai D; Malkoski SP
Lung Cancer; 2017 Jul; 109():28-35. PubMed ID: 28577946
[TBL] [Abstract][Full Text] [Related]
6. Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors.
Haeger SM; Thompson JJ; Kalra S; Cleaver TG; Merrick D; Wang XJ; Malkoski SP
Oncogene; 2016 Feb; 35(5):577-586. PubMed ID: 25893305
[TBL] [Abstract][Full Text] [Related]
7. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
[TBL] [Abstract][Full Text] [Related]
8. RGS6 suppresses TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancers via a novel mechanism dependent on its interaction with SMAD4.
Wang Z; Chen J; Wang S; Sun Z; Lei Z; Zhang HT; Huang J
Cell Death Dis; 2022 Jul; 13(7):656. PubMed ID: 35902557
[TBL] [Abstract][Full Text] [Related]
9. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
[TBL] [Abstract][Full Text] [Related]
10. Correlation between loss of Smad4 and clinical parameters of non-small cell lung cancer: an observational cohort study.
Guo X; Li M; Wang X; Pan Y; Li J
BMC Pulm Med; 2021 Apr; 21(1):111. PubMed ID: 33794845
[TBL] [Abstract][Full Text] [Related]
11. Nomograms incorporating genetic variants in BMP/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for non-small cell lung cancer.
Yang J; Xu T; Gomez DR; Yuan X; Nguyen QN; Jeter M; Song Y; Komaki R; Hu Y; Hahn SM; Liao Z
Cancer Med; 2018 Jun; 7(6):2247-2255. PubMed ID: 29745043
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
Fan K; Zhang CL; Qi YF; Dai X; Birling Y; Tan ZF; Cao F
Biomed Res Int; 2020; 2020():2380124. PubMed ID: 33299862
[TBL] [Abstract][Full Text] [Related]
13. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
14. Expression Signature and Role of miR-30d-5p in Non-Small Cell Lung Cancer: a Comprehensive Study Based on in Silico Analysis of Public Databases and in Vitro Experiments.
Gao L; He RQ; Wu HY; Zhang TT; Liang HW; Ye ZH; Li ZY; Xie TT; Shi Q; Ma J; Hu XH; Chen G
Cell Physiol Biochem; 2018; 50(5):1964-1987. PubMed ID: 30396166
[TBL] [Abstract][Full Text] [Related]
15. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.
Cai D; Hu C; Li L; Deng S; Yang J; Han-Zhang H; Li M
Cancer Med; 2020 Jan; 9(1):84-93. PubMed ID: 31709742
[TBL] [Abstract][Full Text] [Related]
16. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
17. Serum MiRNA as Predictive and Prognosis Biomarker in Advanced Stage Non-small Cell Lung Cancer in Indonesia.
Hanafi AR; Jayusman AM; Alfasunu S; Sadewa AH; Pramono D; Heriyanto DS; Haryana SM
Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):321-332. PubMed ID: 32283582
[TBL] [Abstract][Full Text] [Related]
18. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
[TBL] [Abstract][Full Text] [Related]
19. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
20. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
